Natera (NASDAQ:NTRA) Insider Sells $479,970.00 in Stock

Key Points

• Solomon Moshkevich, an insider at Natera, sold 3,000 shares of the company's stock for approximately $479,970, reducing his ownership by 2.49% to a total of 117,559 shares valued at around $18.8 million.
• Natera reported a revenue of $546.60 million for the last quarter, exceeding analyst expectations, but reported a loss per share of ($0.74), missing the consensus estimate.
• The company has received generally positive ratings from analysts, with a consensus target price of $192.88, reflecting a robust outlook despite the recent insider trading activity.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the transaction, the insider directly owned 117,559 shares in the company, valued at $18,808,264.41. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, September 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.62, for a total value of $499,860.00.
• On Thursday, August 14th, Solomon Moshkevich sold 875 shares of Natera stock. The shares were sold at an average price of $155.46, for a total value of $136,027.50.
• On Friday, August 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $132.89, for a total value of $398,670.00.
• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $308,420.86.
• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $40,533.39.

Natera Trading Up 0.4%

NASDAQ NTRA opened at $161.61 on Thursday. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The firm has a market capitalization of $22.18 billion, a P/E ratio of -84.61 and a beta of 1.74. The firm's fifty day simple moving average is $160.22 and its two-hundred day simple moving average is $156.35.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same period in the prior year, the company posted ($0.30) EPS. The firm's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Natera by 79.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company's stock worth $3,086,000 after acquiring an additional 8,635 shares during the period. GAMMA Investing LLC raised its stake in shares of Natera by 18,607.6% in the first quarter. GAMMA Investing LLC now owns 119,916 shares of the medical research company's stock worth $16,957,000 after purchasing an additional 119,275 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Natera by 10.9% during the first quarter. Rhumbline Advisers now owns 153,402 shares of the medical research company's stock valued at $21,693,000 after buying an additional 15,121 shares during the last quarter. Harbor Investment Advisory LLC raised its position in Natera by 419.2% in the 1st quarter. Harbor Investment Advisory LLC now owns 1,677 shares of the medical research company's stock worth $237,000 after buying an additional 1,354 shares during the last quarter. Finally, Merit Financial Group LLC lifted its stake in Natera by 168.7% during the 1st quarter. Merit Financial Group LLC now owns 9,369 shares of the medical research company's stock valued at $1,325,000 after acquiring an additional 5,882 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NTRA. Piper Sandler reissued an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Barclays reiterated an "overweight" rating and set a $210.00 price target (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley restated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Natera has an average rating of "Buy" and a consensus target price of $192.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.